En esta página
PYXS Pyxis Oncology, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 13, 2026
$2,14
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$1,03mínimo 52 semanas
$5,55máximo 52 semanas
Capitalización Bursátil (MRQ)
$136M
P/E
-1.7
BPA
$-1.28
Ingresos
$14M
tus insignias
Rango 52S
$1–$6
Calificación del Analista
STRONG BUY
Precio Objetivo
$9
P/E
-1.7
ROE
-112.9%
Margen de Beneficio Neto
-574.5%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
PYXS Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$2.14
Capitalización Bursátil (MRQ)
$136M
P/E
-1.7
BPA
$-1.28
Ingresos
$14M
ROE
-112.9%
Rango 52S
$1–$6
PYXS Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$14M2024-12-31 → 2025-12-31
BPA$-1.282021-12-31 → 2025-12-31
Flujo de caja libre$-64M2021-12-31 → 2025-12-31
Margen neto-574.5%2024-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | PYXS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -1.7promedio 5A ≈-0.9 | ≈-0.9 | · | · | |
| P/S | 9.7 | · | 4.9 | Valor razonable | |
| P/C (MRQ) | 11.9promedio 5A ≈1.0 | ≈1.0 | 2.8 | Sobrevalorado | |
| Price / FCF (Precio / FCF) | -2.1promedio 5A ≈-3.4 | ≈-3.4 | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -2.1promedio 5A ≈-3.5 | ≈-3.5 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 2.5promedio 5A ≈0.9 | ≈0.9 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | PYXS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Operating Margin (Margen Operativo) | -609.2% | · | -226.0% | Débil | |
| EBITDA Margin (Margen EBITDA) | -576.6% | · | -226.0% | Débil | |
| Pretax Margin (Margen antes de impuestos) | -564.6% | · | -398.8% | Por debajo del promedio | |
| Net Profit Margin (Margen de Beneficio Neto) | -574.5% | · | -220.0% | Débil | |
| ROA | -64.0%promedio 5A ≈-50.4% | ≈-50.4% | -34.3% | Débil | |
| ROE | -112.9%promedio 5A ≈-76.3% | ≈-76.3% | -61.9% | Débil | |
| ROIC | -160.9% | · | -67.3% | Débil |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | PYXS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Ratio corriente (MRQ) | 1.3promedio 5A ≈7.7 | ≈7.7 | 7.5 | Baja liquidez | |
| Quick Ratio (Ratio Rápido) | 3.2promedio 5A ≈7.4 | ≈7.4 | 7.1 | Baja liquidez |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | PYXS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | -14.2% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | PYXS | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.1 | · | 0.1 | Débil | |
| Revenue / Employee (Ingresos / Empleado) | ≈$247.5K | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
4.3%
Próximo informe
Nov 02, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 19, 2026 | $-0.40 | $-0.36 | -11.0% |
| 31 de marzo de 2026 | May 14, 2026 | $-0.37 | $-0.38 | 1.7% |
| 31 de diciembre de 2025 | $-0.29 | $-0.34 | 15.6% | |
| 30 de septiembre de 2025 | $-0.35 | $-0.35 | -1.4% | |
| 30 de junio de 2025 | $-0.30 | $-0.36 | 16.4% | |
| 31 de marzo de 2025 | $-0.35 | $-0.30 | -16.7% | |
| 31 de diciembre de 2024 | $-0.25 | $-0.34 | 25.7% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue | $14M | $16M | |
| Cost of Revenue | $2M | $475.0K | |
| R&D Expense | $74M | $59M | |
| SG&A Expense | $22M | $25M | |
| Operating Income | $-84M | $-89M | |
| Interest Income | $650.0K | $930.0K | |
| Other Non-op | $6M | $10M | |
| Pretax Income | $-78M | $-79M | |
| Income Tax | $1M | $-2M | |
| Net Income | $-80M | $-77M | |
| EPS (Basic) | $-1.28 | $-1.32 | |
| EPS (Diluted) | $-1.28 | $-1.32 | |
| Shares (Basic) | 62,143,166 | 58,445,765 | |
| Shares (Diluted) | 62,143,166 | 58,445,765 | |
| EBITDA | $-80M | $-86M |
Balance general
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $15M | $19M | |
| Short-term Investments | $51M | $107M | |
| Prepaid Expense | $4M | $4M | |
| Other Current Assets | $626.0K | $434.0K | |
| Current Assets | $72M | $132M | |
| PP&E (Net) | $8M | $10M | |
| PP&E (Gross) | $15M | $15M | |
| Accum. Depreciation | $7M | $5M | |
| Intangibles | $0 | $3M | |
| Total Assets | $92M | $157M | |
| Accounts Payable | $11M | $5M | |
| Accrued Liabilities | $9M | $11M | |
| Current Liabilities | $21M | $18M | |
| Capital Leases | $17M | $19M | |
| Deferred Tax | · | $0 | |
| Total Liabilities | $38M | $36M | |
| Common Stock | $63.0K | $60.0K | |
| Paid-in Capital | $496M | $484M | |
| Retained Earnings | $-443M | $-364M | |
| AOCI | $53.0K | $170.0K | |
| Stockholders' Equity | $53M | $121M | |
| Liabilities + Equity | $92M | $157M | |
| Shares Outstanding | 62,690,229 | 59,967,814 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| D&A | $5M | $3M | |
| Stock-based Comp | $12M | $13M | |
| Deferred Tax | $0 | $-2M | |
| Other Non-cash | $-193.0K | $4M | |
| Operating Cash Flow | $-64M | $-58M | |
| CapEx | $9.0K | $237.0K | |
| Investing Cash Flow | $59M | $8M | |
| Financing Cash Flow | $594.0K | $59M | |
| Net Change in Cash | $-4M | $10M | |
| Taxes Paid | $1M | $164.0K | |
| Free Cash Flow | $-64M | $-58M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -609.2% | -554.1% | |
| Net Margin | -574.5% | -479.0% | |
| Pretax Margin | -564.6% | -492.3% | |
| EBITDA Margin | -576.6% | -535.6% | |
| ROA | -64.0% | -46.7% | |
| ROE | -112.9% | -56.4% | |
| ROIC | -160.9% | -72.1% |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 3.4 | 7.5 | |
| Quick Ratio | 3.2 | 7.2 |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 |
Por Acción
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Book Value / Share | $0.85 | $2.01 | |
| Revenue / Share | $0.22 | $0.28 | |
| Cash Flow / Share | $-1.02 | $-0.99 | |
| Cash / Share | $0.25 | $0.32 | |
| EPS (TTM) | $-1.28 | $-1.32 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | -14.2% | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $14M | $16M | |
| Net Income TTM | $-80M | $-77M | |
| Market Cap | $72M | $94M | |
| P/E | -0.9 | -1.2 | |
| P/S | 5.2 | 5.8 | |
| P/B | 1.3 | 0.8 | |
| P / Tangible Book | 1.3 | 0.8 | |
| P / Cash Flow | -1.1 | -1.6 | |
| P / FCF | -1.1 | -1.6 | |
| Earnings Yield | -111.3% | -84.6% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $11M | $0 | $3M | · | $0 | $0 | $0 | $16M | |
| Cost of Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $475.0K | |
| R&D Expense | $16M | $20M | $22M | $18M | $17M | $17M | $14M | $18M | $14M | $13M | |
| SG&A Expense | $10M | $4M | $5M | $6M | $5M | $6M | $5M | $6M | $6M | $8M | |
| Operating Expenses | $26M | $24M | · | · | $23M | $23M | · | · | · | · | |
| Operating Income | $-26M | $-24M | $-18M | $-23M | $-20M | $-23M | $-40M | $-24M | $-20M | $-6M | |
| Interest Income | $61.0K | $218.0K | $225.0K | $242.0K | $99.0K | $84.0K | $87.0K | $194.0K | $387.0K | $262.0K | |
| Other Non-op | $644.0K | $1M | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $2M | |
| Pretax Income | $-25M | · | $-17M | $-22M | $-18M | · | $-38M | $-21M | $-17M | · | |
| Income Tax | $0 | · | $1M | $0 | $283.0K | · | · | · | · | · | |
| Net Income | $-25M | $-23M | $-18M | $-22M | $-18M | $-21M | $-36M | $-21M | $-17M | $-3M | |
| EPS (Basic) | $-0.40 | $-0.37 | $-0.28 | $-0.35 | $-0.30 | $-0.35 | $-0.62 | $-0.35 | $-0.29 | $-0.06 | |
| EPS (Diluted) | $-0.40 | $-0.37 | $-0.28 | $-0.35 | $-0.30 | $-0.35 | $-0.62 | $-0.35 | $-0.29 | $-0.06 | |
| Shares (Basic) | 63,991,609 | 63,469,850 | · | 62,557,386 | 61,918,826 | 61,048,948 | · | 60,715,041 | 60,495,675 | 51,289,284 | |
| Shares (Diluted) | 63,991,609 | 63,469,850 | · | 62,557,386 | 61,918,826 | 61,048,948 | · | 60,715,041 | 60,495,675 | 51,289,284 | |
| EBITDA | $-26M | $-24M | · | $-23M | $-20M | $-22M | · | $-24M | $-20M | $-4M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $6M | $15M | $9M | $11M | $13M | $19M | $12M | $25M | $28M | |
| Short-term Investments | $14M | $35M | $51M | $67M | $78M | $93M | $107M | $133M | $131M | $129M | |
| Receivables | · | · | · | · | $3M | · | · | · | · | $8M | |
| Prepaid Expense | $2M | $3M | $4M | $5M | $7M | $5M | $4M | $3M | $4M | $6M | |
| Other Current Assets | · | · | $626.0K | · | · | · | $434.0K | · | · | · | |
| Current Assets | $37M | $46M | $72M | $83M | $100M | $112M | $132M | $149M | $161M | $172M | |
| PP&E (Net) | $7M | $8M | $8M | $8M | $9M | $9M | $10M | $10M | $11M | $11M | |
| PP&E (Gross) | · | · | $15M | · | · | · | $15M | · | · | · | |
| Accum. Depreciation | · | · | $7M | · | · | · | $5M | · | · | · | |
| Intangibles | · | · | $0 | $2M | $2M | $3M | $3M | $24M | $24M | $24M | |
| Total Assets | $55M | $64M | $92M | $106M | $123M | $136M | $157M | $195M | $208M | $220M | |
| Accounts Payable | $3M | $5M | $11M | $10M | $9M | $3M | $5M | $5M | $5M | $2M | |
| Accrued Liabilities | $12M | $10M | $9M | $8M | $7M | $10M | $11M | $14M | $10M | $11M | |
| Current Liabilities | $27M | $17M | $21M | $19M | $18M | $14M | $18M | $20M | $17M | $14M | |
| Capital Leases | $16M | $16M | $17M | $17M | $18M | $18M | $19M | $19M | $19M | $20M | |
| Deferred Tax | · | · | · | · | · | · | · | $2M | $2M | $2M | |
| Total Liabilities | $43M | $33M | $38M | $37M | $36M | $33M | $36M | $42M | $39M | $36M | |
| Common Stock | $63.0K | $63.0K | $63.0K | $62.0K | $62.0K | $62.0K | $60.0K | $59.0K | $59.0K | $59.0K | |
| Paid-in Capital | $503M | $498M | $496M | $494M | $491M | $488M | $484M | $481M | $477M | $474M | |
| Retained Earnings | $-492M | $-466M | $-443M | $-425M | $-403M | $-385M | $-364M | $-328M | $-307M | $-289M | |
| AOCI | $-4.0K | $0 | $53.0K | $69.0K | $-5.0K | $49.0K | $170.0K | $351.0K | $-102.0K | $-60.0K | |
| Stockholders' Equity | $11M | $31M | $53M | $69M | $88M | $103M | $121M | $154M | $170M | $184M | |
| Liabilities + Equity | $55M | $64M | $92M | $106M | $123M | $136M | $157M | $195M | $208M | $220M | |
| Shares Outstanding | 63,434,936 | 62,831,246 | 62,690,229 | 62,149,664 | 62,018,135 | 61,631,376 | 59,967,814 | 59,449,998 | 58,914,712 | 58,803,126 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $301.0K | $459.0K | $3M | $527.0K | $535.0K | $552.0K | $550.0K | $731.0K | $585.0K | $1M | |
| Stock-based Comp | $6M | $1M | $2M | $3M | $3M | $4M | $3M | $3M | $3M | $4M | |
| Other Non-cash | · | $-4M | · | · | · | $-6M | · | · | · | $-23M | |
| Operating Cash Flow | $-18M | $-26M | $-10M | $-13M | $-17M | $-23M | $-19M | $-15M | $-3M | $-21M | |
| CapEx | · | · | $0 | · | · | · | $0 | $0 | $0 | $237.0K | |
| Investing Cash Flow | $21M | $16M | $16M | $11M | $15M | $16M | $27M | $-8.0K | $4.0K | $-18M | |
| Financing Cash Flow | $10M | $-25.0K | $669.0K | $-8.0K | $-67.0K | $0 | $50.0K | $2M | $110.0K | $58M | |
| Net Change in Cash | $13M | $-10M | $7M | $-2M | $-2M | $-7M | $7M | $-13M | $-3M | $18M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-21M |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | -700.4% | · | · | · | · | -34.7% | |
| Net Margin | · | · | · | · | -650.9% | · | · | · | · | -20.2% | |
| Pretax Margin | · | · | · | · | -640.8% | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | -700.4% | · | · | · | · | -27.8% | |
| ROA | -28.5% | -23.2% | · | -14.6% | -11.1% | -11.9% | · | -11.1% | -9.0% | -1.6% | |
| ROE | -51.2% | -34.6% | · | -19.8% | -14.3% | -14.7% | · | -14.5% | -11.0% | -1.9% | |
| ROIC | -227.2% | · | · | · | -22.9% | · | · | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 2.8 | · | 4.3 | 5.7 | 7.8 | · | 7.3 | 9.5 | 12.2 | |
| Quick Ratio | 1.2 | 2.5 | · | 3.9 | 5.2 | 7.3 | · | 7.1 | 9.2 | 11.7 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | 0.0 | · | · | · | · | 0.1 | |
| Receivables Turnover | · | · | · | · | 1.9 | · | · | · | · | 4.0 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.18 | $0.50 | · | $1.11 | $1.41 | $1.67 | · | $2.58 | $2.88 | $3.13 | |
| Revenue / Share | · | · | · | · | $0.05 | · | · | · | · | $0.31 | |
| Cash Flow / Share | · | $-0.41 | · | · | · | $-0.37 | · | · | · | $-0.40 | |
| Cash / Share | $0.30 | $0.09 | · | $0.14 | $0.17 | $0.21 | · | $0.20 | $0.43 | $0.48 | |
| EPS (TTM) | $-1.40 | $-1.30 | · | $-1.62 | $-1.62 | $-1.61 | · | $-1.04 | $-1.25 | $-1.37 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | $16M | · | · | · | · | |
| Net Income TTM | $-89M | $-82M | · | $-97M | $-96M | $-95M | · | $-57M | $-59M | $-58M | |
| Market Cap | $191M | $92M | · | $138M | $68M | $60M | · | $218M | $195M | $251M | |
| P/E | -2.1 | -1.1 | · | -1.4 | -0.7 | -0.6 | · | -3.5 | -2.6 | -3.1 | |
| P/S | · | · | · | · | · | 3.7 | · | · | · | · | |
| P/B | 16.7 | 2.9 | · | 2.0 | 0.8 | 0.6 | · | 1.4 | 1.1 | 1.4 | |
| P / Tangible Book | 16.7 | 2.9 | · | 2.1 | 0.8 | 0.6 | · | 1.7 | 1.3 | 1.6 | |
| P / Cash Flow | · | -3.5 | · | · | · | -2.7 | · | · | · | -12.1 | |
| Earnings Yield | -46.5% | -89.0% | · | -73.0% | -147.3% | -164.3% | · | -28.3% | -37.8% | -32.2% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $14M | $16M | · | · | · |
| Margen Operativo % | -609.2% | -554.1% | · | · | · |
| Beneficio neto | $-80M | $-77M | $-74M | $-121M | $-76M |
| EPS Diluido | $-1.28 | $-1.32 | $-1.85 | $-3.65 | $-8.95 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ratio corriente | 3.4 | 7.5 | 4.8 | · | 14.9 |
| Ratio Rápido | 3.2 | 7.2 | 4.6 | · | 14.7 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $-64M | $-58M | $-77M | · | $-36M |
Propietarios institucionales (13F) 87 declarantes · $105.2M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
87
Valor en tenencia
$105.2M
Nuevas posiciones
12
Posiciones cerradas
9
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 12 (-3 vs trimestre anterior) | 9 (-2 vs trimestre anterior) | 26 (+15 vs trimestre anterior) | 25 (-13 vs trimestre anterior) | +7.0M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| GordonMD Global Investments LP | $30 174 976 | 10 024 909 | 28,68% | Acciones |
| Pfizer Inc | $19 480 773 | 7 032 770 | 18,51% | Acciones |
| Laurion Capital Management LP | $14 751 673 | 4 900 888 | 14,02% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $6 248 751 | 2 075 997 | 5,94% | Acciones |
| Atle Fund Management AB | $2 909 041 | 966 459 | 2,76% | Acciones |
| VANGUARD GROUP INC | $2 686 133 | 2 335 768 | 2,55% | Acciones |
| BlackRock, Inc. | $2 612 481 | 867 934 | 2,48% | Acciones |
| Palo Alto Investors LP | $2 601 474 | 864 277 | 2,47% | Acciones |
| MARSHALL WACE, LLP | $2 499 936 | 830 544 | 2,38% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $2 324 418 | 772 232 | 2,21% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $1 782 698 | 591 849 | 1,69% | Acciones |
| Woodline Partners LP | $1 577 237 | 523 999 | 1,50% | Acciones |
| 683 Capital Management, LLC | $1 382 695 | 459 367 | 1,31% | Acciones |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1 290 104 | 428 606 | 1,23% | Acciones |
| DIADEMA PARTNERS LP | $1 168 482 | 388 200 | 1,11% | Opción de compra |
| Longaeva Partners L.P. | $1 064 282 | 353 582 | 1,01% | Acciones |
| Decheng Capital LLC | $983 698 | 326 810 | 0,93% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $911 988 | 302 986 | 0,87% | Acciones |
| JANE STREET GROUP, LLC | $873 171 | 290 090 | 0,83% | Acciones |
| STATE STREET CORP | $748 999 | 248 837 | 0,71% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $701 342 | 233 004 | 0,67% | Acciones |
| UBS Group AG | $467 203 | 155 217 | 0,44% | Acciones |
| Bank of New York Mellon Corp | $403 328 | 133 996 | 0,38% | Acciones |
| NORTHERN TRUST CORP | $373 117 | 123 959 | 0,35% | Acciones |
| NewEdge Wealth, LLC | $349 178 | 116 006 | 0,33% | Acciones |
| XTX Topco Ltd | $333 926 | 110 939 | 0,32% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $252 723 | 83 961 | 0,24% | Acciones |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $244 593 | 81 260 | 0,23% | Acciones |
| BANK OF AMERICA CORP /DE/ | $242 197 | 80 464 | 0,23% | Acciones |
| JANE STREET GROUP, LLC | $221 837 | 73 700 | 0,21% | Opción de compra |
| STIFEL FINANCIAL CORP | $212 015 | 70 437 | 0,20% | Acciones |
| Cable Car Capital, LP | $185 434 | 61 606 | 0,18% | Acciones |
| MYDA Advisors LLC | $150 500 | 50 000 | 0,14% | Acciones |
| Qube Research & Technologies Ltd | $150 295 | 49 932 | 0,14% | Acciones |
| UNIVERSITY OF CHICAGO | $146 680 | 48 731 | 0,14% | Acciones |
| CITADEL ADVISORS LLC | $142 424 | 47 317 | 0,14% | Acciones |
| Quadrature Capital Ltd | $141 672 | 47 067 | 0,13% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $139 062 | 46 200 | 0,13% | Opción de compra |
| GOLDMAN SACHS GROUP INC | $138 159 | 45 900 | 0,13% | Acciones |
| Verdad Advisers, LP | $135 146 | 44 899 | 0,13% | Acciones |
| LPL Financial LLC | $131 098 | 43 554 | 0,12% | Acciones |
| COMMONWEALTH EQUITY SERVICES, LLC | $127 790 | 42 455 | 0,12% | Acciones |
| J. Derek Lewis & Associates Inc. | $126 420 | 42 000 | 0,12% | Acciones |
| CITIGROUP INC | $114 997 | 38 205 | 0,11% | Acciones |
| SIMPLEX TRADING, LLC | $114 085 | 37 902 | 0,11% | Acciones |
| Point72 Asset Management, L.P. | $111 647 | 37 092 | 0,11% | Acciones |
| Walleye Capital LLC | $110 702 | 36 778 | 0,11% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $108 887 | 36 175 | 0,10% | Acciones |
| MORGAN STANLEY | $100 679 | 33 448 | 0,10% | Acciones |
| MACKENZIE FINANCIAL CORP | $79 292 | 26 343 | 0,08% | Acciones |
Activistas y propietarios del %+ 5 2 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Lara Sullivan, M.D. ×2 presentaciones | 2 de abril de 2025 | 11,21% | Enmienda | · | SEC |
| Lara Sullivan ×4 presentaciones | 3 de abril de 2024 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 17 insiders · 8 directivos · 9 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Thomas Civik | CEO & Chairman of the Board | 4 de septiembre de 2026 A | 206 186 | 0 | 0 | $0 |
| Lara Sullivan, M.D. | President ,CEO & CMO | 31 de marzo de 2025 A | 2 403 882 | 0 | 0 | $0 |
| Connealy Pamela Yanchik | CFO & COO | 31 de marzo de 2025 A | 1 199 143 | 0 | 0 | $0 |
| Ritu Shah | Chief Operating Officer | 7 de octubre de 2021 A | · | 0 | 0 | $0 |
| Jitendra Wadhane | Prin Fin & Acct Officer | 24 de marzo de 2026 A | 512 882 | 0 | 0 | $0 |
| Ken Kobayashi | Chief Medical Officer | 29 de diciembre de 2023 A | · | 0 | 0 | $0 |
| Jay Feingold | Chief Medical Officer | 24 de marzo de 2023 A | 730 345 | 0 | 0 | $0 |
| Ronald Herbst | Chief Scientific Officer | 7 de octubre de 2021 A | · | 0 | 0 | $0 |
| Jakob Dupont | Consejero | 20 de agosto de 2026 A | 38 741 | 0 | 1 | $-107 100 |
| Santhosh Palani | Consejero | 24 de marzo de 2026 A | 6 000 | 0 | 0 | $0 |
| Darren S Cline | Consejero | 24 de marzo de 2026 A | 251 405 | 0 | 0 | $0 |
| Rachel Humphrey | Consejero | 24 de marzo de 2026 A | 81 309 | 0 | 3 | $-15 865 |
| Michael A Metzger | Consejero | 24 de marzo de 2026 A | · | 0 | 0 | $0 |
| Freda C Lewis-Hall | Consejero | 24 de marzo de 2026 A | 241 405 | 0 | 0 | $0 |
| John L Flavin | Consejero | 24 de marzo de 2026 A | 413 015 | 0 | 0 | $0 |
| BARCLAYS PLC | Propietario del 10% | 26 de abril de 2022 | · | 0 | 0 | $0 |
| Mark Chin | · | 21 de abril de 2022 S | 0 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 5 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IWC · iShares Trust | 0,04% | 165 468 SH | 11 de septiembre de 2026 | Diario |
| IBB · iShares Trust | 0,02% | 513 768 SH | 11 de septiembre de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,01% | 5 892 SH | 2 de octubre de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 600 185 SH | 19 de agosto de 2026 | Diario |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 422 296 SH | 19 de agosto de 2026 | Diario |
PYXS Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 16 analistas
COMPRA
Objetivo mediano
$8.00
+273,8%
7 43,8%
Compra fuerte
7 43,8%
Compra
2 12,5%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
9 analistas · 2026-10-04Objetivo medio $8.67 +305,0%
← Por Debajo de Todos los Objetivos
Precio Actual $2.14
Mín$6.00
Media$8.67
Máx$19.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | · |
| ELDN | $114M | -2.9 | · | · | -69.4% | · |
| CUE | $29M | -1.1 | 195.8% | -96.9% | -119.3% | · |
| NKTX | $131M | -1.3 | · | · | -31.1% | · |
| CHRS | $172M | 1.0 | 59.8% | 398.4% | 185.8% | · |
| CNTN | $112M | -2.7 | · | · | -18.0% | · |
| DTIL | $100M | -1.2 | -50.1% | -133.4% | -72.4% | · |
| ALXO | $61M | -0.6 | · | · | -225.0% | · |
| ORGO | $658M | 34.5 | 17.0% | 6.6% | 13.9% | · |
| AVXL | · | -16.5 | -36.1% | -991.4% | · | · |
| VYGR | $232M | -1.9 | -49.5% | -296.5% | -54.4% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 13, 2026